Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1988 Oct;85(20):7719–7723. doi: 10.1073/pnas.85.20.7719

Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.

L K Gilliland 1, M R Clark 1, H Waldmann 1
PMCID: PMC282264  PMID: 3140243

Abstract

Previous studies have demonstrated that bispecific hybrid antibodies produced by cell-cell fusion or chemically conjugated heteroaggregates can direct cytotoxic T lymphocytes to kill target cells for which they have no intrinsic specificity, a phenomenon we call effector cell retargeting (ECR). These studies used bispecific reagents with one specificity directed to CD3 or Ti on the effector cell and the other directed to a target cell antigen. To avoid the need to create different hybrid hybridomas for each target antigen we have developed a universal means to elicit ECR through the use of an antiglobulin step. We have constructed a bispecific hybrid antibody with dual specificity for CD3 and a rat immunoglobulin light chain allotype. This bispecific antibody could mediate ECR to a range of target cells, each coated with distinct surface-binding rat monoclonal antibodies. A particular advantage of targeting to surface-bound monoclonal antibodies is that all other available effector systems may also attack the same antibody-coated target cell.

Full text

PDF
7721

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bindon C. I., Hale G., Clark M., Waldmann H. Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen. Synergy and interference in complement-mediated lysis. Transplantation. 1985 Nov;40(5):538–544. doi: 10.1097/00007890-198511000-00013. [DOI] [PubMed] [Google Scholar]
  2. Clark M. R. The detection and characterization of antigen-specific monoclonal antibodies using anti-immunoglobulin isotype antibodies coupled to red blood cells. Methods Enzymol. 1986;121:548–556. doi: 10.1016/0076-6879(86)21054-x. [DOI] [PubMed] [Google Scholar]
  3. Clark M. R., Waldmann H. T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies. J Natl Cancer Inst. 1987 Dec;79(6):1393–1401. [PubMed] [Google Scholar]
  4. Cobbold S. P., Thierfelder S., Waldmann H. Immunosuppression with monoclonal antibodies. A model to determine the rules for effective serotherapy. Mol Biol Med. 1983 Oct;1(3):285–304. [PubMed] [Google Scholar]
  5. Corvalan J. R., Smith W. Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids. Cancer Immunol Immunother. 1987;24(2):127–132. doi: 10.1007/BF00205589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hale G., Clark M., Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol. 1985 May;134(5):3056–3061. [PubMed] [Google Scholar]
  7. Herlyn D., Herlyn M., Steplewski Z., Koprowski H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol. 1979 Aug;9(8):657–659. doi: 10.1002/eji.1830090817. [DOI] [PubMed] [Google Scholar]
  8. Karawajew L., Micheel B., Behrsing O., Gaestel M. Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorter. J Immunol Methods. 1987 Feb 11;96(2):265–270. doi: 10.1016/0022-1759(87)90323-1. [DOI] [PubMed] [Google Scholar]
  9. Karpovsky B., Titus J. A., Stephany D. A., Segal D. M. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J Exp Med. 1984 Dec 1;160(6):1686–1701. doi: 10.1084/jem.160.6.1686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lanzavecchia A., Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol. 1987 Jan;17(1):105–111. doi: 10.1002/eji.1830170118. [DOI] [PubMed] [Google Scholar]
  11. Leeuwenberg J. F., Spits H., Tax W. J., Capel P. J. Induction of nonspecific cytotoxicity by monoclonal anti-T3 antibodies. J Immunol. 1985 Jun;134(6):3770–3775. [PubMed] [Google Scholar]
  12. Levy R., Miller R. A. Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Annu Rev Med. 1983;34:107–116. doi: 10.1146/annurev.me.34.020183.000543. [DOI] [PubMed] [Google Scholar]
  13. Liu M. A., Kranz D. M., Kurnick J. T., Boyle L. A., Levy R., Eisen H. N. Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8648–8652. doi: 10.1073/pnas.82.24.8648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Milstein C., Cuello A. C. Hybrid hybridomas and their use in immunohistochemistry. Nature. 1983 Oct 6;305(5934):537–540. doi: 10.1038/305537a0. [DOI] [PubMed] [Google Scholar]
  15. Perez P., Hoffman R. W., Shaw S., Bluestone J. A., Segal D. M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985 Jul 25;316(6026):354–356. doi: 10.1038/316354a0. [DOI] [PubMed] [Google Scholar]
  16. Perez P., Hoffman R. W., Titus J. A., Segal D. M. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies. J Exp Med. 1986 Jan 1;163(1):166–178. doi: 10.1084/jem.163.1.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rosenberg S. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985 Oct;75(4):595–603. [PubMed] [Google Scholar]
  18. Shen L., Guyre P. M., Anderson C. L., Fanger M. W. Heteroantibody-mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-gamma and is not blocked by human IgG. J Immunol. 1986 Dec 1;137(11):3378–3382. [PubMed] [Google Scholar]
  19. Springer T. A., Bhattacharya A., Cardoza J. T., Sanchez-Madrid F. Monoclonal antibodies specific for rat IgG1, IgG2a, and IgG2b subclasses, and kappa chain monotypic and allotypic determinants: reagents for use with rat monoclonal antibodies. Hybridoma. 1982;1(3):257–273. doi: 10.1089/hyb.1.1982.1.257. [DOI] [PubMed] [Google Scholar]
  20. Staerz U. D., Bevan M. J. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1453–1457. doi: 10.1073/pnas.83.5.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Staerz U. D., Kanagawa O., Bevan M. J. Hybrid antibodies can target sites for attack by T cells. Nature. 1985 Apr 18;314(6012):628–631. doi: 10.1038/314628a0. [DOI] [PubMed] [Google Scholar]
  22. Suresh M. R., Cuello A. C., Milstein C. Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7989–7993. doi: 10.1073/pnas.83.20.7989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Suresh M. R., Cuello A. C., Milstein C. Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol. 1986;121:210–228. doi: 10.1016/0076-6879(86)21019-8. [DOI] [PubMed] [Google Scholar]
  24. Watt S. M., Gilmore D. J., Metcalf D., Cobbold S. P., Hoang T. K., Waldmann H. Segregation of mouse hemopoietic progenitor cells using the monoclonal antibody, YBM/42. J Cell Physiol. 1983 Apr;115(1):37–45. doi: 10.1002/jcp.1041150107. [DOI] [PubMed] [Google Scholar]
  25. Webb K. S., Ware J. L., Parks S. F., Walther P. J., Paulson D. F. Evidence for a novel hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy. Cancer Treat Rep. 1985 Jun;69(6):663–672. [PubMed] [Google Scholar]
  26. Wong J. T., Colvin R. B. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol. 1987 Aug 15;139(4):1369–1374. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES